Aquestive Therapeutics (AQST) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Aquestive Therapeutics (AQST) over the last 6 years, with Q3 2025 value amounting to -$0.14.
- Aquestive Therapeutics' EPS (Weighted Average and Diluted) fell 769.23% to -$0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.71, marking a year-over-year decrease of 5434.78%. This contributed to the annual value of -$0.51 for FY2024, which is 29147.96% down from last year.
- Latest data reveals that Aquestive Therapeutics reported EPS (Weighted Average and Diluted) of -$0.14 as of Q3 2025, which was down 769.23% from -$0.14 recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.11 during Q1 2023, and its lowest value of -$0.76 during Q4 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.2 (2024), whereas its average is -$0.22.
- Per our database at Business Quant, Aquestive Therapeutics' EPS (Weighted Average and Diluted) plummeted by 37664.91% in 2021 and then surged by 13437.5% in 2023.
- Aquestive Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.76 in 2021, then skyrocketed by 66.66% to -$0.25 in 2022, then surged by 48.71% to -$0.13 in 2023, then tumbled by 51.27% to -$0.2 in 2024, then grew by 28.81% to -$0.14 in 2025.
- Its last three reported values are -$0.14 in Q3 2025, -$0.14 for Q2 2025, and -$0.24 during Q1 2025.